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ABSTRACT
Introduction: Moxidectin is a milbemycin endectocide recently approved for the treatment of human 
onchocerciasis. Onchocerciasis, earmarked for elimination of transmission, is a filarial infection endemic 
in Africa, Yemen, and the Amazonian focus straddling Venezuela and Brazil. Concerns over whether the 
predominant treatment strategy (yearly mass drug administration (MDA) of ivermectin) is sufficient to 
achieve elimination in all endemic foci have refocussed attention upon alternative treatments. 
Moxidectin’s stronger and longer microfilarial suppression compared to ivermectin in both phase II 
and III clinical trials indicates its potential as a novel powerful drug for onchocerciasis elimination.
Areas covered: This work summarizes the chemistry and pharmacology of moxidectin, reviews the 
phase II and III clinical trials evidence on tolerability, safety, and efficacy of moxidectin versus ivermec-
tin, and discusses the implications of moxidectin’s current regulatory status.
Expert opinion: Moxidectin’s superior clinical performance has the potential to substantially reduce 
times to elimination compared to ivermectin. If donated, moxidectin could mitigate the additional 
programmatic costs of biannual ivermectin distribution because, unlike other alternatives, it can use the 
existing community-directed treatment infrastructure. A pediatric indication (for children <12 years) and 
determination of its usefulness in onchocerciasis–loiasis co-endemic areas will greatly help fulfill the 
potential of moxidectin for the treatment and elimination of onchocerciasis.
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1. Introduction
Human onchocerciasis is a neglected tropical disease (NTD) 
caused by the filarial nematode Onchocerca volvulus 
(Filarioidea: Onchocercidae) and transmitted via the bites of 
Simulium (Diptera: Simuliidae) blackfly vectors. Onchocerciasis 
is the second leading cause of infectious blindness globally 
after trachoma, but it also causes skin lesions, depigmentation 
(leopard skin), and debilitating ‘troublesome itch’ in addition 
to excess mortality in those heavily infected, partly because of 
its association with epilepsy [1,2]. Given the clustering of dis-
ease near rivers, where the blackflies breed, the disease is 
colloquially termed ‘river blindness’ [1,2].
The lifecycle of O. volvulus comprises a human stage and 
a vector stage, with the blackfly vector having its own distinct 
(holometabolous) lifecycle. Humans are the definitive host of 
the parasite, harboring adult worm stages known as macro-
filariae, with lifespans (mean age to death) of approximately 
10 years (with some worms potentially living for at least 
20 years). Macrofilariae are dioecious, with distinct sexual 
dimorphism. Adult female worms must mate with male 
worms to begin production of the progeny stage, termed 
microfilariae, which live, on average, for approximately 
9–12 months and are responsible for the pathology associated 
with onchocerciasis. Blackflies can ingest skin-dwelling micro-
filariae when taking a blood meal on an infected human by 
virtue of their pool-feeding mechanism. Microfilariae ingested 
during a bloodmeal migrate through the blackfly’s peritrophic 
matrix, abdominal epithelium, and hemocoel to reach the 
thoracic muscles, where, in competent vectors, they develop 
into infective (L3) larvae in about a week, depending on 
environmental conditions. L3 larvae are released from the 
fly’s mouth-parts upon a subsequent blood meal, into the 
wound created by the feeding blackfly, and develop into 
adult worms (in about 12–18 months) to complete the 
cycle [1].
Estimates of the number of O. volvulus-infected people 
globally range from 17 to 37 million, with 99% of the cases 
in 31 countries of Sub-Saharan Africa. The disease is also 
endemic in Yemen and the Amazonian focus straddling 
Venezuela and Brazil, and has been eliminated from other 
foci in Meso (Mexico, Guatemala) and South America (northern 
Venezuela, Colombia, Ecuador) [3]. The burden of disease 
caused by onchocerciasis has been significantly reduced 
from 1,442,000 (95% uncertainty interval = 835,000–2,289,000) 
disability-adjusted life years (DALYs) in 2005 to 1,340,000 
(639,000–2,370,000) in 2017 (a reduction of 7%) due to large- 
scale interventions [4]. The first control program in Africa, the 
Onchocerciasis Control Programme in West Africa (OCP, 
1974–2002), averted an estimated 600,000 cases of blindness 
in 11 countries [1]. The African Programme for Onchocerciasis 
Control (APOC, 1995–2015), extended control efforts to the 
remaining 20 endemic countries in Africa not covered by the 
OCP, averting a further 200,000 cases of blindness between 
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1995 and 2011 [5]. Upon APOC’s closure in December 2015, 
the Expanded Special Project for the Elimination of Neglected 
Tropical Diseases (ESPEN) was created, to provide technical 
support to the endemic countries in their efforts to eliminate 
onchocerciasis [2]. In January 2012, and on occasion of the 
London Declaration on NTDs, the World Health Organization 
(WHO) launched a roadmap for accelerating progress against 
NTDs [6] and proposed the goal of eliminating onchocerciasis 
where feasible by 2020. This was later revised by the Joint 
Action Forum (JAF) of APOC to become elimination in 80% of 
endemic countries by 2025 [7]. In 2019, the WHO launched 
a consultation process for revising the roadmap toward 2030 
and beyond [8].
Since 1989, onchocerciasis control has relied on the mass 
drug administration (MDA) of (donated) ivermectin 
(Mectizan®), a broad-spectrum antiparasitic macrocyclic lac-
tone. Ivermectin’s effects on O. volvulus include 
a microfilaricidal (killing of microfilariae), an embryostatic 
(temporary inhibition of microfilarial release from female 
worms), a (modest) permanent sterilizing, and a (partial) 
macrofilaricidal (killing of macrofilariae) action [9,10] (see 2.3. 
Pharmacodynamics and antiparasitic effects in onchocerciasis). 
Distribution of ivermectin in Africa is predominantly by annual 
community-directed treatment with ivermectin (aCDTI), 
whereby trained members of the local community act as 
community drug distributors (CDDs) year on year. Despite 
elimination successes in some foci of Mali, Senegal, Nigeria, 
Sudan, and Uganda [11,12] (some under biannual, 6-monthly, 
treatment), others are not on track to reach the proposed 
elimination goals with aCDTI or exhibit ‘sub-optimal’ 
responses (SOR) to the drug [2,11] (see 4.1.4. Settings that 
have reported sub-optimal responses to ivermectin for 
a discussion on these).
Consequently, attention has focused on identifying alter-
native treatment strategies (ATS) aimed at accelerating pro-
gress toward elimination of transmission [13]. ATS include (not 
mutually exclusively) enhancing existing CDTI by increasing 
geographic and therapeutic coverage as well as treatment 
adherence; increasing treatment frequency (e.g. to biannual 
CDTI (bCDTI) or quarterly (3-monthly) treatment where neces-
sary); deploying ground-based focal vector control (in contrast 
with the logistically demanding and large-scale aerial vector 
larviciding operations undertaken by the OCP); and using 
novel therapeutics [14]. Moxidectin represents a prime exam-
ple of the latter, having been recently been approved by the 
US Food & Drug Administration (FDA) for the treatment of 
humans with onchocerciasis due to O. volvulus [15]. Hailing 
from the field of veterinary medicine, moxidectin is also 
a macrocyclic lactone and a potent microfilaricide, with 
a seemingly more prolonged microfilaricidal and/or embryo-
static effect than ivermectin. Phase II and III clinical trials have 
demonstrated moxidectin’s superior clinical performance com-
pared to ivermectin [16,17], indicating its potential to accel-
erate and enhance the feasibility of onchocerciasis elimination.
This review presents an overview of the chemistry, phar-
macology, tolerability, safety, and efficacy of moxidectin for 
the treatment of human onchocerciasis. It outlines unmet 
therapeutic needs, summarizes the regulatory status of mox-
idectin for human use, and provides an expert commentary on 
how moxidectin could be used within the current landscape of 
onchocerciasis treatment, control, and elimination.
2. Overview of moxidectin
2.1. Chemistry
Moxidectin is a semi-synthetic macrocyclic lactone of the mil-
bemycin class of macrolide antibiotics. It is derived by chemi-
cal optimization of F-alpha or nemadectin (LL F-2924α), 
a fermentation product of the bacterium Streptomyces cyano-
griseus ssp. noncyanogenus, through the addition of 
a methoxime moiety at carbon 23 [18]. Moxidectin differs 
from ivermectin (also a macrocyclic lactone but of the aver-
mectin family) in the absence of a disaccharide attached to 
carbon 13, the presence of an olefinic side chain at carbon 25, 
and a methoxime moiety at carbon 23. The chemical struc-
tures of ivermectin and moxidectin are compared in [18].
2.2. Pharmacokinetics and metabolism
Moxidectin is classified as a Biopharmaceutics Classification 
System Class II (high permeability, low solubility) compound. 
Absorption is fast, with a time to peak concentration (tmax) of 
Article highlights
Ⴠ Moxidectin is a milbemycin endectocide that has been used to treat 
nematode and ectoparasitic infections of livestock and companion 
animals and has recently been approved by the FDA for the treat-
ment of onchocerciasis in humans aged ≥12 years.
Ⴠ Moxidectin (8 mg) exerts a potent microfilaricidal effect (killing of 
Onchocerca volvulus microfilariae) and a prolonged suppression of 
microfilaridermia, which may result from a strong embryostatic effect 
(temporary inhibition of microfilarial production by adult female 
worms), although other mechanisms cannot be ruled out.
Ⴠ Moxidectin is not considered to be curative or macrofilaricidal (killing 
of adult worms), but data on repeated treatments with long follow- 
up times are currently lacking to rigorously evaluate this.
Ⴠ In healthy volunteers, moxidectin was well tolerated in the range of 
3–36 mg investigated in phase I clinical trials; this range includes the 
recommended 8 mg therapeutic dose against human onchocerciasis. 
In O. volvulus-infected patients, moxidectin treatment was associated 
with an increased incidence of adverse events associated with micro-
filaricidal activity compared to ivermectin, but nearly all were mild to 
moderate, did not require medical intervention, and were self- 
limiting.
Ⴠ Moxidectin showed impressive efficacy in both phase II and phase III 
clinical trials. Compared to ivermectin, the current gold-standard 
treatment for onchocerciasis, moxidectin achieved significantly 
more complete and sustained microfilaridermia clearance.
Ⴠ Other alternative treatments for onchocerciasis include (curative) 
anti-Wolbachia therapies. Unlike moxidectin, which could be deliv-
ered through established community-directed treatment platforms in 
Africa, currently available anti-Wolbachia therapies (e.g. doxycycline) 
require a 4–6-week course of 100 mg per day, complicating their use 
in community treatment programs. Other anti-Wolbachia compounds 
in pre-clinical development may be efficacious with shorter (1–-
2-week) courses. Combination therapies using anti-Wolbachia drugs 
plus moxidectin could, respectively, deliver macrofilaricidal and 
microfilaricidal efficacy superior to the combination with ivermectin.
Ⴠ Moxidectin represents a promising alternative to ivermectin for the 
treatment and control of onchocerciasis, capable of accelerating or 
increasing the feasibility of elimination in endemic areas. To fulfil this 
potential, it is imperative that an appropriate pediatric dose and 
formulation of moxidectin be developed and approved.
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3–4 hours [19–21]. Peak plasma concentration (Cmax) and total 
area under the concentration–time curve (AUC0–∞) showed 
a linear increase with a dose within the range (3–36 mg) 
investigated [19,20]. A liquid formulation of moxidectin has 
approximately 30% higher Cmax and AUC0–∞, and a tmax nearly 
an hour earlier than a tablet formulation [21], although the 
liquid formulation resulted in only modestly increased bioa-
vailability (1.29 fold) relative to the tablet formulation and 
marginally more rapid absorption. A high-fat breakfast (co- 
administration with lipids) is associated with increased expo-
sure and a delayed tmax [19,22], but the increases are not 
clinically relevant and moxidectin can be dosed without 
regard to food. Once absorbed, moxidectin has a large appar-
ent volume of distribution and a half-life of 20–43 days in 
human beings [19,21], compared to approximately 1 day for 
ivermectin [23]. Moxidectin is also more lipophilic than iver-
mectin (partition coefficient of logP = 6 for moxidectin and 
logP = 4.8 for ivermectin), which may result in greater reten-
tion in adipose tissue, which may help explain moxidectin’s 
long half-life [24]. In vitro studies using mammalian liver 
microsomes suggested that moxidectin is a limited substrate 
of CYP-metabolism (cytochrome P450 3A and cytochrome 
P450 2B [25]), with no evidence for non-CYP-mediated meta-
bolism. In humans, moxidectin is minimally metabolized 
within the body and did not affect the pharmacokinetics of 
midazolam, a sensitive CYP3A4 substrate [26]. Moxidectin, 
therefore, exhibits no clinically relevant cytochrome P450- 
related drug–drug interactions.
Moxidectin is excreted, mostly unmetabolized [27], in feces. 
A small amount of moxidectin is excreted into the breast milk 
of lactating women (relative infant dose ~9% of the maternal 
dose), who otherwise have identical pharmacokinetics to 
healthy males [28]. Moxidectin is a poor substrate for 
P-glycoprotein (P-gp) transporters [29,30], being mostly 
excreted via a P-gp-independent pathway into the intestine 
[31]. Intestinal, biliary, and mammary excretion is thought to 
be through Breast Cancer Resistance Protein (BCRP or ABCG2) 
[32] unlike ivermectin, for which P-gp transporters appear to 
be important for both biliary and intestinal secretion [31]. 
However, moxidectin is effluxed by P-gp transporters at the 
blood–brain barrier [31], suggesting that tissue-specific P-gp 
transporters interact with moxidectin differently. Drug efflux at 
the blood–brain barrier, and/or lower intrinsic activity than 
ivermectin on mammalian GABA receptors seemingly lower 
the neurotoxicity of moxidectin compared to ivermectin in 
dogs and mice [33,34]. The elimination (or lack thereof) of 
moxidectin through P-gp or similar routes is likely to contri-
bute to the drug’s long half-life and overall efficacy, with the 
potential for parasites’ (cumulative) exposure to moxidectin 
far exceeding that of ivermectin. Despite the long half-life, 
systemic exposure is relatively low from 72 hours post- 
treatment, with plasma concentrations lower than 3 ng/mL 
after an 8 mg oral dose.
Nematodes express P-gp in the pharynx, intestine, head 
neurons, and the uteri of female worms [35,36]. The compel-
ling, albeit indirect, evidence that nematodes P-gp transpor-
ters can efflux macrocyclic lactones [37–39], with P-gp 
expression increasing after in vivo parasites’ exposure to 
macrocyclic lactones [40,41], is implicated in macrocyclic lac-
tone resistance [42]. It has been hypothesized that P-gp trans-
porters act to limit drug concentrations within the parasite 
and can alter the drug’s efficacy [42]. Therefore, moxidectin’s 
limited interaction with P-gp may play a role in its increased 
efficacy [29]. However, there still is no direct evidence of 
macrocyclic lactone efflux by nematode P-gp transporters, 
and the pharmacokinetics within the parasites remain far 
from clear.
2.3. Pharmacodynamics and antiparasitic effects in 
onchocerciasis
Moxidectin exerts both stronger and longer suppression of 
O. volvulus microfilaridermia than ivermectin [16,17]. Its micro-
filaricidal effect leads to near-complete clearance of skin 
microfilariae, with peak clearance at around 1 month after 
treatment, and little variability in inter-individual responses. 
Ivermectin clears, on average, 98–99% of skin microfilariae, 
with maximum clearance at 1–2 months after treatment [9], 
with more pronounced inter-individual variability. Microfilariae 
are thought to be paralyzed by ivermectin and transported 
from the skin to the sub-epidermal layers and other organs 
(e.g. spleen), where they are killed by the body’s immune 
system [43]; however, the occurrence of Mazzotti reactions 
suggests some microfilarial killing in the skin. Other proposed 
mechanisms include disruption of the excretory-secretory 
apparatus of microfilariae which leads to disruption of the 
host–pathogen molecular negotiation via suppression of para-
site protein secretion [44].
Similar studies have yet to be conducted for moxidectin to 
ascertain the body sites where processing of the microfilariae 
takes place and to assess its effect on the excretory-secretory 
apparatus of microfilariae. With moxidectin, low skin microfi-
larial loads are sustained, with many individuals having no 
detectable microfilariae (by skin-snip microscopy) 6 months 
after treatment [16]. Ivermectin has a similar, albeit weaker 
and shorter, suppression of microfilariae that is attributed to 
an ‘embryostatic’ effect (suppression of microfilarial release 
from female worms in treated individuals). Adult female 
worms gradually resume the release of microfilariae 
3–4 months after ivermectin treatment [9]. Given the relative 
similarity of the two drugs, and the observed dynamics of skin 
repopulation, it has been conjectured that moxidectin’s longer 
suppression of skin microfilariae suggests a more potent and 
prolonged embryostatic effect [45], although other mechan-
isms cannot be ruled out. Figure 1 presents the microfilarial 
dynamics following a single dose of ivermectin (Figure 1(a)) or 
moxidectin (Figure 1(b)).Repeated doses of ivermectin are 
postulated (through modeling of data from Ghana [46]) to 
effect a cumulative (and irreversible) sterilizing effect on 
adult worms, estimated at around 30–35% reduction in 
microfilarial productivity per dose [47]. However, field studies 
in Cameroon [48] and modeling of data from Guatemala [49] 
and Cameroon [10] reported little evidence of a cumulative 
effect of repeated ivermectin doses on female worm fecund-
ity. A macrofilaricidal effect of (annual and quarterly) iver-
mectin treatments has been documented in field trials [50] 
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and its magnitude (50% and 70% reduction in adult worm 
life-expectancy, respectively) has been estimated through 
modeling [10]. A recent analysis of the data collected in 
[50] suggests that quarterly ivermectin treatments may 
reduce the incidence of new nodules compared to annual 
treatments [51]. We emphasize that the estimation of both 
cumulative and macrofilaricidal effects of ivermectin required 
modeling analysis of longitudinal data on repeated (annual, 
biannual, quarterly) treatments [46,50,52]. Such data have 
not yet been collected and modeled for moxidectin and, 
therefore, there is currently no direct evidence of moxidec-
tin’s potential sterilizing and/or macrofilaricidal effects. The 
more prolonged embryostatic effect of moxidectin that has 
been used in modeling studies [45] has been assumed by 
analogy with the observed microfilarial pharmacodynamics 
after a single (standard, 150 µg/kg of body weight) dose of 
ivermectin [9,45]. A prophylactic effect of monthly and quar-
terly ivermectin and moxidectin treatments on O. ochengi 
(the closest relative of O. volvulus) has been documented in 
its cattle host [53].
The principal mechanism of antiparasitic action for moxi-
dectin is thought to be as for ivermectin’s, mediated by glu-
tamate-gated chloride channels (GluCls) of the target 
helminths [54]. This binding acts to increase channel perme-
ability, with the influx of chloride ions resulting in dysfunction 
of the excretory pore, flaccid paralysis, and death of the para-
site through host response. X-ray crystallography showed iver-
mectin to be capable of binding to the transmembrane 
domain of GluCl in the Caenorhabditis elegans (free-living) 
nematode model system [55]. Although research has not 
mostly focused on O. volvulus (for which no satisfactory animal 
model exists), GluCl genes are highly conserved across filarial 
nematodes [56–58]. Homology modeling (based on Brugia 
malayi Bm-GluCl), used together with computer-based dock-
ing of moxidectin’s 3-dimensional ligand site, suggests that 
GluCl binding should be conserved with moxidectin [58], with 
in vitro studies showing that moxidectin increases GluCl chan-
nel activity [59,60]. Although no direct binding has been 
observed between moxidectin and ligand-gated chloride 
channels, in vitro assays suggest that worm paralysis requires 
concentrations of ivermectin and moxidectin [61] 2–3 orders 
of magnitude higher than the peak plasma levels achieved 
in vivo [23,62]. At such high concentrations (well above phar-
macologically relevant concentrations), macrocyclic lactones 
can act as agonists for gamma-aminobutyric acid (GABA)- 
gated chloride channels, that could contribute to worm 
paralysis in motility assays [54]. The lack of effect on parasite 
motility at pharmacologically relevant concentrations suggests 
that parasite paralysis in the skin may not be a macrocyclic 
lactones’ mechanism of action. Other potential mechanisms of 
action include altering the secretion of immunomodulatory 
proteins and molecules reducing the parasite’s ability to 
evade host immune responses [44]. In Brugia malayi, ivermec-
tin has been demonstrated also to disrupt the function of the 
excretory-secretory apparatus of microfilariae, supporting the 
argument that ivermectin treatment in human filariases, 
including onchocerciasis, leads to disruption of the host– 
pathogen molecular negotiation via suppression of parasite 
protein secretion [44]. Such mechanisms may be responsible 
for differences in drug efficacy between in vitro and in vivo 
studies.
Note that macrocyclic lactones also have activity against 
invertebrate ectoparasites (such as ticks), as well as other 
parasitic nematodes [24]. Discussion of these is beyond the 
scope of this review, but we recommend Prichard et al. [24] for 
a detailed review of these topics.
(a) Ivermectin (b) Moxidectin
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Figure 1. The observed and modeled skin microfilarial dynamics following a single dose of: (a) ivermectin (150 µg/kg) and (b) moxidectin (8 mg).
The data points (from the phase II clinical trial conducted by [16]) represent the percentage from pre-treatment mean microfilarial (mf) load (four skin snips from each participant) at 8 days 
and 1, 3, 6, 12, and 18 months after treatment for: (a) 45 ivermectin-treated participants (black triangles); (b) 38 moxidectin-treated participants (black diamonds). By way of model 
validation, the blue solid line in (a) illustrates the dynamics derived from the equations and parameters presented in [9] rather than re-fitted to the data in [16]. The red solid line in (b) 
represents the use of the modeling framework of [9] to fit the data in [16]. Error bars show the 95% CIs around the proportional reduction in mean mf counts, illustrating their variability 
among participants in the two trial arms depicted here. The data points at 8 days and 1, 3, and 6 months post-8 mg moxidectin are narrower than the plotted data and so are not 
discernible. To enable better visualization of post-treatment data points, the y-axis has been plotted from 0% to 30% (in both panels, the percentage at pre-treatment would be 100%). This 
figure has been reproduced under the Creative Commons Attribution 4.0 International License (CC BY 4.0) from [45]. 
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2.4. Resistance
Resistance to ivermectin has not been documented in humans. 
However, studies in Ghana of populations repeatedly treated 
with ivermectin have reported so-called ‘suboptimal’ responses 
(SOR) to ivermectin, phenotypically characterized by faster (poor 
responses) than expected (good responses) rates of skin repopu-
lation by O. volvulus microfilariae [63,64]. SORs have been pro-
posed to occur because of a reduction in ivermectin’s 
embryostatic effect (manifested as an earlier resumption of 
microfilarial production by female worms). Worms extracted 
from thus characterized ‘poor’ and ‘good’ responders in Ghana 
and Cameroon populations have been analyzed with genome- 
wide approaches to understand the genetic basis of this appar-
ent loss of ivermectin sensitivity [65]. According to the SOR 
definition, however, and in the moxidectin vs. ivermectin clinical 
trials (see 3. Clinical trials of moxidectin), individuals who were 
ivermectin naïve showed SORs following ivermectin but not 
moxidectin treatment [17], indicating that a high degree of inter- 
individual variability in responses to ivermectin is present before 
wide-spread and prolonged treatment [66]. Smaller levels of 
inter-individual variability in responses to moxidectin suggest 
that the drug could be useful in communities with increased 
frequency of ivermectin SORs.
Resistance to moxidectin (and to ivermectin) is common in 
parasitic nematodes of livestock and companion animals [67]. 
Even in resistant populations, moxidectin retains a higher effi-
cacy than the avermectins, but continued exposure can result 
in therapeutic failure and cross-resistance between moxidectin 
and ivermectin [67]. The genetic analysis of O. volvulus taken 
from poor and good responders in Ghana and Cameroon 
found that decreased ivermectin efficacy in human onchocer-
ciasis may be determined by (geographically different) quan-
titative trait loci, mostly unrelated to the few candidate genes 
and mechanisms that had been proposed in resistance studies 
of veterinary parasitic nematodes [66]. In Haemonchus contor-
tus, a major quantitative trait locus has been established to be 
associated with ivermectin resistance [68], suggesting that the 
mechanisms of ivermectin resistance in parasites of humans 
and farmed ruminants may be somewhat distinct. However, if 
moxidectin were widely adopted for large-scale treatment of 
onchocerciasis and other endo/ectoparasitic infections of 
humans, it would be essential to regularly monitor its efficacy, 
and understand its impact on the genetic diversity and struc-
ture of O. volvulus (and other parasite) populations. This is 
particularly important for onchocerciasis for which the ulti-
mate goal is global elimination (i.e. reducing the potentially 
rescuing effect that untreated refugia could have on the 
spread of SORs, but see [69] for a review of the conventional 
wisdom of, and challenges to the concept of refugia in miti-
gating anthelmintic resistance).
3. Clinical trials of moxidectin
3.1. Safety and tolerability
Multiple phase I studies, first by Cotreau et al. [19] and subse-
quently by Korth-Bradley et al. [21,22,26,28] and Kinrade et al. 
[20], established that the safety and tolerability of moxidectin 
are very similar to placebo in healthy volunteers. Moxidectin 
doses ranging from 3 to 36 mg were well tolerated with no 
severe adverse events (SAEs) and mild/moderate adverse 
events (AEs) such as headache. There was no increase in 
incidence, nature, or severity of AEs with increasing dose 
[19–21]. Up to the maximum 36 mg dose tested, moxidectin 
did not prolong the QT interval [20]. (A drug’s influence on 
cardiac repolarization is assessed by detecting prolongation of 
the QT interval, which represents the duration of ventricular 
depolarization and subsequent repolarization; QT prolonga-
tion is a biomarker for a drug’s risk of causing arrhyth-
mias [70].)
In the treatment of onchocerciasis patients, moxidectin 
results in the same risk management profile as ivermectin. 
The incidence and severity of AEs were similar between mox-
idectin and ivermectin. Rapid microfilarial death in infected 
patients can result in AEs, including pruritus, rash, tachycardia, 
and orthostatic hypotension as part of the so-called Mazzotti 
reactions (complex, acute inflammatory responses mounted 
by the immune system after administration of microfilaricides). 
Both phase II and phase III clinical trials monitored basic vital 
signs as well as monitoring of AEs and SAEs including Mazzotti 
reactions. Nearly all patients in either treatment arm in both 
phase II and III trials had some form of Mazzotti reaction but 
events were transient and self-limiting. Nearly all non-Mazzotti 
AEs and all SAEs were unrelated to the drug administration. 
Treatment groups with higher microfilarial loads were more 
likely to suffer reactions [16,17], unsurprising given that 
Mazzotti reactions are correlated with skin microfilarial density 
[71]. In the phase II trial, the 8 mg moxidectin group showed 
a statistically significant (p < 0.05) increase in the occurrence 
of rash and pruritus, as well as increased pulse rate and 
hypotension compared to ivermectin. There was no significant 
difference between ivermectin and moxidectin 2 mg, although 
4 mg showed a significant increase in hypotension compared 
to ivermectin. In the much larger phase III trial, the frequency, 
nature, and severity of Mazzotti reactions were very similar 
between ivermectin and 8 mg moxidectin. Moxidectin signifi-
cantly increased (Onchocerciasis Chemotherapy Research 
Centre grade 4) Mazzotti reactions (p < 0.01), primarily attrib-
uted to increased rates of hypotension. No patient in either 
trial required major clinical intervention for a Mazzotti reac-
tion. In the phase II trial, all rashes resolved without interven-
tion with only one severely infected participant treated with 
2 mg moxidectin requiring chlorpheniramine to relieve prur-
itus symptoms. Hypotension, in both phase II and III trials, 
required no treatment beyond lying down for a few minutes.
To date, no study has been conducted to investigate the 
safety of using moxidectin in O. volvulus–Loa loa co-infected 
individuals. Ivermectin can cause SAEs, including potentially 
fatal encephalopathy, in individuals with high L. loa microfilar-
emia [72]. The pathophysiology of such SAEs is poorly under-
stood but it appears to have an immunological basis, involving 
interleukin (IL)5-driven eosinophilia and eosinophil activation 
(positively correlated with pre-treatment microfilarial count) in 
the mechanism of microfilarial killing by ivermectin in loiasis 
[73]. Given moxidectin’s strong microfilaricidal effect and over-
all similarity to ivermectin, it will be crucial to determine the 
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safety of moxidectin for the treatment of onchocerciasis in 
loiasis co-endemic areas, its efficacy for the treatment of loia-
sis, and the immunological mechanisms involved in the killing 
of L. loa microfilariae and any subsequent AEs.
3.2. Clinical efficacy against O. volvulus
3.2.1. Phase II trial
The phase II trial compared 2, 4, and 8 mg doses of moxidectin 
to the standard ivermectin dose (150 µg/kg, translating into 6, 
9, or 12 mg doses according to the weight range of partici-
pants in the 8 mg moxidectin arm) [16,45]. Male and female 
participants between the ages of 18 and 60 years and with 
O. volvulus infection (determined by identification of microfi-
lariae in skin snips) were recruited from the River Tordzi basin 
in South-eastern Ghana, from communities with no previous 
history of vector control or ivermectin MDA.
Notable exclusion criteria included pregnancy or breast-
feeding, anti-filarial therapy within the previous 5 years, and 
loiasis co-infection. A total of 172 patients were recruited with 
166 (96.5%) completing the study. The trial used a 3ฉ1 mox-
idectinฉivermectin randomization ratio, such that the ivermec-
tin control arm and the 3 moxidectin dose arms each 
contained approximately 45 patients. Patients were further 
stratified by pre-treatment skin microfilarial load as: mild 
(<10 microfilariae/mg skin and no ocular involvement), mod-
erate (10–20 microfilariae/mg skin and low ocular involve-
ment), and severe (>20 microfilariae/mg skin and with or 
without ocular involvement), with approximately 50% of 
recruited patients in the severe infection category. Drug effi-
cacy was monitored based primarily on skin microfilarial den-
sity using a total of 4 skin snips taken from the right and left 
iliac crests and calves before and 8 days and 1, 2, 3, 6, 12, and 
18 months after treatment.
All three moxidectin doses (2, 4, and 8 mg) achieved both 
faster and considerably more complete skin microfilarial clear-
ance than ivermectin. For all three moxidectin doses, the 
number of patients with undetectable levels of skin microfilar-
iae was statistically significantly greater than with ivermectin, 
with the difference reaching significance as soon as 8 days 
after treatment with 4 and 8 mg moxidectin. For the 8 mg 
dose, the proportion of participants with undetectable skin 
microfilariae was significantly higher than that for 2 and 4 mg 
moxidectin at 12 and 18 months after treatment. The average 
annual reduction in skin microfilarial density was 88% for 
ivermectin, compared to 97%, 98%, and 98% for 2, 4, 8 mg 
moxidectin, respectively. Microfilaridermia began increasing 
after 2 months for ivermectin, after 3 months for 2 mg mox-
idectin, after 6 months for 4 mg, and after 12 months for 8 mg 
moxidectin.
The trial also looked at the proportion of live female macro-
filariae in (a total of 214) onchocercomata (O. volvulus nodules) 
excised from 126 patients (all treatment groups) at 18 months 
after treatment and reported this to be 50% (n = 92 female 
worms, 95% confidence interval (95% CI) = 40–60%) for ivermec-
tin; 64% (n = 115, 95% CI = 54–72%) for 2 mg moxidectin; 68% 
(n = 90, 95% CI = 58–77%) for 4 mg, and 72% (n = 65, 95% 
CI = 60–82%) for 8 mg moxidectin. Although these proportions 
are statistically significantly different between ivermectin and 
moxidectin 4 mg (p = 0.0147), and ivermectin and moxidectin 
8 mg (p = 0.0051), they are not significantly different between 
ivermectin and 2 mg moxidectin or between the three moxidec-
tin dose groups. The authors of the trial questioned the true 
significance of their adult worm analysis given the small sample 
size, pre-treatment imbalance between treatment groups and 
the possibility that the excised macrofilariae may not have been 
truly representative of an individual’s total macrofilarial load [16]. 
They concluded that their analysis was insufficiently powered to 
quantify treatment effects on macrofilariae. Interestingly, how-
ever, the proportion of live female worms in the ivermectin 
group (50%) and the three moxidectin groups (64–72%) falls 
within the range of variation modeled by Walker et al. [10] 
when estimating the macrofilaricidal effect of one (annual) 
round of ivermectin in the field trial conducted by Gardon et al. 
[50] in Cameroon [10].
3.2.2. Phase III trial
The Phase III trial was a randomized, double-blind trial directly 
comparing the efficacy of 8 mg moxidectin vs. 150 μg/kg 
ivermectin [17] (see 3.2.1. Phase II trial for a range of ivermec-
tin doses in mg). Male and female participants aged ≥12 years 
and infected with O. volvulus infection were recruited from 
communities in Ghana, Liberia, and the Democratic Republic 
of the Congo (DRC), none of which had received CDTI. Notable 
exclusion criteria included: pregnancy or breastfeeding; har-
boring <10 microfilariae/mg as assessed by skin snip; co- 
infection with lymphatic filariasis or loiasis, and having 
received anthelmintic treatment in the past 6 months. After 
screening, a total of 1,472 participants were randomized at 
a 2:1 ratio to the moxidectin or ivermectin control arms. The 
primary measure of efficacy was again skin microfilarial density 
(by four skin snips as described above in the phase II trial) 1, 6, 
12, and 18 months after treatment compared to microfilarial 
density before treatment. Moxidectin 8 mg resulted in lower 
skin microfilarial loads than ivermectin at the 1-, 6-, 12- and 
18-month follow-up times. At 12 months, the (geometric) 
mean microfilarial load in the moxidectin group (0.6 microfi-
lariae/mg, 95% CI = 0.3–1.0) was statistically significantly lower 
than that in the ivermectin group (4.5 microfilariae/mg, 95% CI 
= 3.5–5.9; p < 0.0001; treatment difference 86.7%), and this 
reduction was independent of sex, but greater (93%) in those 
with ≥20 microfilariae/mg before treatment than in those with 
<20 microfilariae/mg (76%) before treatment. Significantly 
more participants maintained undetectable skin microfilariae 
in the moxidectin group (360/938 = 38%) than in the ivermec-
tin group (7/478 = 1.5%) (p < 0.0001) between 1 and 
12 months after treatment.
Table 1 summarizes AEs of moxidectin in comparison to 
ivermectin from the results of the phase II and III clinical trials 
described above, and Table 2 presents the efficacy against 
O. volvulus of moxidectin vs. ivermectin in those trials.
4. Overview of unmet needs regarding the 
treatment of onchocerciasis
Given the superior microfilaricidal efficacy of moxidectin, as 
demonstrated in the above-described clinical trials (section 3.2. 
6 P. MILTON ET AL.
Clinical efficacy against O. volvulus), it is important to consider 
what would be the role that moxidectin could play in helping to 
fill unmet therapeutic needs for the treatment, control, and 
elimination of onchocerciasis. Therefore, we describe below the 
epidemiological scenarios in which ivermectin distribution 
would be insufficient and how moxidectin could help achieve 
or accelerate elimination of transmission goals [8]. We also dis-
cuss the development of novel macrofilaricides, particularly 
those based on anti-Wolbachia action, which could potentially 
be combined with moxidectin to harness superior macro- and 
microfilaricidal activity. For a review of research on new drugs for 
the elimination of onchocerciasis in Africa see [14].
4.1. Major impediments to onchocerciasis elimination
4.1.1. Settings with a long-term history of 
community-directed treatment with ivermectin (CDTI)
Some communities have received many years of CDTI but 
have made somewhat limited progress toward elimination 
[74–76]. This may be due to low levels of therapeutic coverage 
(proportion of the total population taking the drug on a given 
treatment round) and/or high levels of systematic non- 
adherence (proportion of the population never taking treat-
ment) due to programmatic constraints [77], with untreated 
(or infrequently treated) individuals maintaining microfilarial 
loads that contribute to transmission. This situation has been 
documented in a number of communities across Africa [78– 
81]. In others, however, although acceptable coverage and 
adherence may be reached and sustained, very high rates of 
transmission (due to high blackfly biting rates and/or intense 
exposure to blackfly bites) can result in substantial inter- 
treatment transmission even if microfilarial loads are low. 
Despite the initial rapid microfilaridermia reduction that fol-
lows ivermectin, adult female worms gradually resume micro-
filarial production 3–4 months after treatment [9]. Therefore, 
as microfilariae repopulate the skin during the period between 
rounds of aCDTI (or even bCDTI), transmission to vectors can 
be considerable in communities with high blackfly biting rates. 
Mathematical modeling studies of onchocerciasis transmission 
suggest that both high endemicity and unsatisfactory cover-
age, adherence, and frequency can hinder elimination [82,83]. 
Moxidectin, delivered through community-directed treatment 
approaches, could replace ivermectin in areas of persistent 
transmission, but it would also necessitate reaching and sus-
taining high levels of therapeutic coverage and adherence. Its 
superior efficacy and more prolonged suppression of micro-
filaridermia levels would help, however, to curtail inter- 
treatment transmission more effectively than ivermectin. 
Modeling studies have suggested that annual community- 
directed treatment with moxidectin (aCDTM) may have 
a similar epidemiological impact to that of bCDTI and mitigate 
against the increased cost of biannual distribution [45].
Table 1. Summary of adverse events (as a percentage of participants with AEs or SAEs) for ivermectin and moxidectin from phase II and III clinical trials.
Awadzi et al. [16] phase II trial Opoku et al. [17] phase III trial
AE category or AE
Ivermectin 
150 µg/kg
Moxidectin 
2 mg
Moxidectin 
4 mg
Moxidectin 
8 mg
Ivermectin 
150 µg/kg
Moxidectin 
8 mg
Any AE 100% (45/45) 97.7% (43/44) 100% (45/45) 97.4% (37/38) – –
SAEs (any grade) – – – – 3.4% (17/494) 4.0% (39/978)
Drug-unrelated AEs 93.3% (42/45) 93.2% (41/44) 91.1% (41/45) 94.7% (36/38) 97.8% (483/494) 97.1% (950/978)
Non-Mazzotti AEs 2.2% (1/45) 0% (0/44) 4.4% (2/45) 2.6% (1/38) 0% 0%
Mazzotti AEs 
(any grade)
95.6% (43/45) 86.4% (38/44) 100% (45/45) 97.4% (37/38) 96.8% (478/494) 98.9% (967/978)
Clinical* Mazzotti reaction (any grade) – – – – 90.3% (446/494) 96.5% (944/978)
Clinical Mazzotti reaction (grade 4)† – – – – 5.1% (25/494) 9.2% (90/978)#
MAP decrease – SAPH (grade 4)† 0% (0/45) 6.8% (3/44) 2.2% (1/45) 15.8% (6/38)# – –
MAP decrease – SSPH (grade 4)† 2.2% (1/45) 2.3% (1/44) 8.9% (4/45) 13.2% (5/38) – –
AE: adverse event; SAE: severe adverse event; *Clinical Mazzotti reactions: non-laboratory reactions; MAP: mean arterial pressure; SAPH: severe asymptomatic 
postural hypotension; SSPH: severe symptomatic postural hypotension; †Onchocerciasis Chemotherapy Research Centre grade 4; #p < 0.05 for pairwise comparison 
of moxidectin treatment group vs. ivermectin treatment group. 
Table 2. Summary of efficacy on Onchocerca volvulus microfilariae for ivermectin and moxidectin from phase II and III clinical trials.
Awadzi et al. [16] phase II trial Opoku et al. [17] phase III trial
Time post-treatment (months)
Ivermectin 
150 µg/kg
Moxidectin 
2 mg
Moxidectin 
4 mg
Moxidectin 
8 mg
Ivermectin 
150 µg/kg
Moxidectin 
8 mg
Percentage of participants with undetectable microfilaridermia (by 4 skin snips)
1 54.8% (23/42) 78.6% (33/42)# 97.8% (44/45)# 97.3% (36/37)# 42.3% (208/492) 83.6% (813/973)#
6 31.0% (13/42) 81.0% (34/42)# 91.1% (41/45)# 100% (37/37)# 11.0% (54/491) 91.6% (881/962)#
12 19.1% (8/42) 35.7% (15/42)# 40.0% (18/45)# 59.5% (22/37)# 5% (24/480) 46.5% (440/947) #
18 14.3% (6/42) 16.7% (7/42) 26.7% (12/45) 35.1% (13/37)# 4.1% (16/386) 28.1% (215/764)#
Percentage reduction from pre-treatment skin microfilarial density
1 91.7% 99.8% 100% 100% 93.9% 99.8%
6 92.3% 99.7% 99.9% 100% 90.9% 99.9%
12 84.1% 96.1% 96.1% 98.2% 76.5% 96.8%
18 81.1% 88.3% 89.5% 92.0% 64.0% 89.1%
#p < 0.05 for pairwise comparison of moxidectin treatment group vs. ivermectin treatment group. 
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4.1.2. Settings with no or very little community-directed 
treatment with ivermectin (CDTI)
Some endemic communities, mostly of low (hypo-)endemicity, 
have remained largely untreated. Within APOC, foci delineated 
as hypoendemic (nodule prevalence <20%, corresponding to 
a skin microfilarial prevalence <35–40% [84]) were not prior-
itized for treatment, partly because of their limited contribu-
tion to onchocerciasis-associated morbidity, and because of 
uncertainty on their ability to maintain autochthonous (ende-
mic) transmission [85]. Thus, it was proposed that eliminating 
O. volvulus in higher endemicity communities would precipi-
tate elimination in (epidemiologically coupled) hypoendemic 
foci. Most communities delineated as hypoendemic occur in 
vast rural areas, with very little detailed information on trans-
mission intensity or endemicity [85,86]. Yet, in-depth epide-
miological evaluations of areas previously delineated as 
hypoendemic have revealed that some areas contained pock-
ets of higher endemicity or were wrongly classified as hypoen-
demic when reassessed using a more sensitive diagnostic [87]. 
There also exist higher endemicity (meso- and hyperendemic) 
communities that should have received treatment (nodule 
prevalence ≥20%, microfilarial prevalence ≥35–40% [84]) but 
which have received none or very few rounds of CDTI because 
of political and social instability (e.g. programs in the DRC, 
Sierra Leone, and South Sudan) [2]. Although ivermectin dis-
tribution may have started in some of these communities, 
progress is far behind compared to elsewhere in Africa. 
Therefore, implementation of aCDTM or biannual CDTM 
(bCDTM) from a very early stage could help accelerate pro-
gress toward elimination (in hypoendemic–mesoendemic set-
tings) or increase its feasibility (in hyperendemic areas).
4.1.3. Settings that are hypoendemic for onchocerciasis 
but co-endemic with loiasis
A major limitation to the implementation of ivermectin MDA 
in communities that are hypoendemic for onchocerciasis but 
co-endemic with loiasis (another filarial infection, caused by 
Loa loa, and distributed in the forest belt of central Africa) is 
the risk of SAEs (e.g. encephalitis, coma, death), following 
microfilaricidal treatment of individuals with heavy L. loa 
microfilaremia [72]. Although Gardon et al. [72] found 
a significantly increased risk of developing prolonged func-
tional impairment above 8,000 L. loa microfilariae/mL of blood, 
and an increased risk of encephalopathy above 30,000 micro-
filariae/mL, others have used ≥20,000 as the SAE threshold 
[88]. Hypoendemic onchocerciasis–loiasis co-endemic areas 
with L. loa prevalence >20% (where it is expected that 2–9% 
of individuals harbor ≥30,000 microfilariae/mL) would be 
excluded from CDTI [13]. In these situations, test-and-not- 
treat (TNT) protocols have been successfully piloted [88] 
which test for L. loa microfilaremia levels in community resi-
dents, and for those harboring levels above those associated 
with SAEs, albendazole (or anti-Wolbachia therapies, see 4.2. 
Other compounds in clinical development), but not ivermec-
tin, may be offered. Although clinical trials have yet to be 
conducted to assess the safety of moxidectin in onchocercia-
sis–loiasis co-endemic areas, it could potentially be used in 
TNT modalities of drug distribution, after having established 
safe (L. loa) microfilaremia thresholds for treatment. Once 
a safe microfilaremia threshold is established, it would also 
be important to determine the efficacy of moxidectin for 
treating (low to moderate) L. loa infection (see [89] for a meta- 
analysis of studies investigating the effect of ivermectin on 
L. loa), and to determine the need to re-test individuals for 
levels of loiasis microfilaremia following initiation of TNT with 
moxidectin.
In areas of meso- and hyperendemic onchocerciasis and co- 
endemic loiasis, it has been considered that the benefits of 
CDTI for onchocerciasis treatment/elimination outweigh the 
risks of SAEs (provided that enhanced surveillance is in place 
for their prompt identification and management [13]), 
although this judgment has attracted criticism and may have 
contributed to the low levels of coverage and adherence to 
treatment in certain settings because of the fears of SAEs [80]. 
If moxidectin were to replace ivermectin in these co-endemic 
settings, it would be essential to evaluate the relative benefits 
and risks of CDTM.
4.1.4. Settings that have reported sub-optimal responses 
to ivermectin
The fourth (and least well-understood) group of potential 
impediments to onchocerciasis elimination refers to the occur-
rence of so-called sub-optimal responses (SORs) to ivermectin 
[63–66], which have been described and discussed in 2.4. 
Resistance. Here we re-iterate the imperative to monitor the 
efficacy of moxidectin should it widely replace ivermectin for 
the treatment, control, and elimination of onchocerciasis, and 
to better understand the impact of MDA on the population 
genetic structure of O. volvulus [65].
4.2. Other compounds in clinical development
Other than moxidectin, the drugs furthest along in clinical and 
pre-clinical development are anti-Wolbachia therapies, target-
ing the endosymbiotic Wolbachia pipientis bacterium within 
the parasite [90–92]. Depletion of Wolbachia (by >90%), fol-
lowing treatment with tetracycline antibiotics such as doxycy-
cline, exerts a potent but protracted macrofilaricidal activity, 
reducing the adult worms’ life-expectancy by 70–80%, from 
approximately 10 years to 2–3 years [93]. This slow-killing 
action contributes to its safety and tolerability profile [91,93]. 
Although not directly microfilaricidal, microfilaridermia loads 
decrease progressively as a result of female worm sterilization 
by inhibition of the parasite’s embryogenesis [90]. 
Furthermore, microfilariae from doxycycline-treated indivi-
duals exhibit retarded development to the infective, L3 
stage, if ingested by blackfly vectors for at least 5 months 
after treatment compared to microfilariae from placebo- 
treated patients [94]. Data from animal models of filariasis 
also show that, during the course of treatment, larvae entering 
the vertebrate host do not establish as adult worms, thereby 
indicating a prophylactic effect [95]. To achieve the critical 
efficacy threshold of >90% Wolbachia depletion [90], a 4–-
6-week course of 100–200 mg of doxycycline is required [93]. 
As L. loa does not harbor W. pipientis, the parasite is unaf-
fected by anti-Wolbachia therapies [96], which can, therefore, 
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be safely used to treat onchocerciasis in loiasis co-endemic 
areas [97].
High levels of coverage (74%) and adherence (98%) with 
a 6-week (100 mg daily) course (for those aged ≥12 years) 
were documented in a feasibility trial of community-directed 
treatment with doxycycline (CDTD) in communities of 
Cameroon co-endemic with loiasis [98]. A significant impact 
on epidemiological indicators (microfilarial prevalence and 
load) was recorded 3–4 years after treatment in doxycycline- 
treated individuals from these communities [99]. The steriliz-
ing and macrofilaricidal efficacy of doxycycline has also been 
demonstrated in communities with documented SORs to iver-
mectin [100]. Treatment with doxycycline in combination with 
ivermectin is highly effective in exerting a prolonged (18- 
month) suppression of microfilarial loads in clinical trials 
[101]. To date, no trial has evaluated the efficacy of moxidectin 
and doxycycline in combination.
The Cameroon CDTD feasibility field trial of Wanji et al. [98] 
employed pre-treatment advocacy meetings and daily mon-
itoring of patients throughout the treatment course delivered 
by community health implementers trained to deliver doxycy-
cline MDA. Such strong community engagement undoubtedly 
contributed to improved coverage and adherence, with a cost 
estimated at USD 2.5 per course per person [98] compared to 
approximately USD 0.50 per treatment for CDTI [102]. 
A preliminary modeling study [103] indicated that CDTD 
would be approximately twice as effective in preventing pre-
valent cases of O. volvulus infection compared to CDTI, and 
more than twice as effective in reducing levels of transmission. 
Moreover, CDTD would be about as cost-effective as CDTI in 
loiasis co-endemic areas, partly because CDTD could be deliv-
ered less frequently than CDTI (e.g. biennially (every 2 years) 
rather than annually), and partly because it would avoid the 
increased costs associated with monitoring and surveillance of 
people treated with ivermectin (in meso- and hyperendemic 
onchocerciasis–loiasis co-endemic areas) to minimize 
SAEs [13].
Despite these favorable arguments, the length of an effica-
cious (at least 5-week) doxycycline course – with which adher-
ence is key – together with treatment contra-indications in 
pregnant women and children aged <8 years (but see 
[104,105]), and the potential risk of increasing antimicrobial 
resistance in other concomitant infections, represent substan-
tial barriers to the widespread implementation of doxycycline 
for community-directed treatment. Therefore, a test-and-treat 
with doxycycline (TTd) strategy (with and without focal 10- 
week vector control through ground larviciding of blackfly 
breeding sites) has been trialed in comparison to routine 
aCDTI in South West Cameroon by the COUNTDOWN 
Consortium [106]. Preliminary modeling results indicate that 
not only is achieving high levels of therapeutic coverage and 
adherence essential (the ‘Td’ component of the strategy), but 
crucially, the coverage of screening for O. volvulus microfilariae 
(the pre-requisite ‘T’ component) must also be high [107].
The anti-Wolbachia consortium (A·WOL) was established to 
find anti-Wolbachia drugs at least as efficacious as doxycycline 
but requiring considerably shorter treatment courses and 
without its contra-indications [91,92]. Other anti-Wolbachia 
drugs that have been trialed in humans include rifampicin 
and moxifloxacin [108] (results yet to be published), and min-
ocycline [109]. Other compounds screened by A∙WOL that 
have shown great promise in pre-clinical development, are 
high-dose rifampicin [110], rifampicin plus albendazole [111], 
and an optimized azaquinazoline (AWZ1066S) [112]. Other 
compounds (in the Drugs for Neglected Diseases initiative 
(DNDi) filariasis portfolio) [113] include oxfendazole (for 
which a phase I trial is being planned through the Helminth 
Elimination Platform (HELP)), emodepside (nearing phase II 
trial in Ghana for safety, tolerability, and dose/regimen selec-
tion), and TylAMacTM (ABBV-4083, developed by A∙WOL in 
partnership with AbbVie [114]), for which a phase II proof-of- 
concept trial is being prepared in the DRC [113].
Table 3 compares the characteristics, pharmacokinetics, 
pharmacodynamics, modalities of distribution in onchocercia-
sis-endemic communities, and regulatory status of ivermectin, 
moxidectin, and doxycycline for the treatment and control of 
O. volvulus infection.
5. Regulatory status of moxidectin
5.1. Approval by the USA Food and Drug Administration 
(FDA)
On 13 June 2018, the FDA approved the use of moxidectin for 
the treatment of human onchocerciasis in patients aged 
12 years and older [15]. The posology is an 8 mg dose (speci-
fically four 2-mg tablets), not dependent on the weight of the 
recipient and without regard to food. (By contrast, ivermectin 
can be used for those aged ≥5 years, and doxycycline for 
patients aged ≥8 years.) The FDA approval does not give any 
explicit contra-indications for moxidectin but notes the lack of 
sufficient data to establish its safety during pregnancy, lacta-
tion, and ages less than 12 years, and provides warnings of 
Mazzotti reactions, worsening of onchodermatitis, symptomatic 
orthostatic hypotension, and SAEs in patients with loiasis. The 
FDA approval package for the drug outlined two post- 
marketing requirements for moxidectin, namely: (i) evaluation 
of pre- and post-natal toxicity assessment in rats, and (ii) con-
duction of a prospective, randomized, ivermectin-controlled 
trial of repeated doses of 8 mg moxidectin for onchocerciasis 
control [15].
5.2. Future trials
The National Institutes of Health (NIH) indicate registration of 
three trials for the treatment of onchocerciasis in preparatory 
stages, aimed at: (i) assessing the safety and efficacy of biann-
ual doses of moxidectin [116], (ii) establishing the appropriate 
dose and formulation of moxidectin for treatment of children 
aged 4 to 11 years [117], and (iii) evaluating the safety and 
efficacy of 2 mg moxidectin in patients with L. loa microfilar-
emia [118].
6. Conclusions
Moxidectin represents a powerful drug, recently incorporated 
into our armory, for the fight against human onchocerciasis 
both in clinical and community settings. To realize its full 
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potential in the latter context, and particularly as a drug sui-
table for MDA, repeated doses and/or increased treatment 
frequency may be necessary. It will also be essential to extend 
the indication to include children under 12. Clinical trials have 
been registered and are in the process of being designed or 
conducted to accomplish these requirements [116,117]. Where 
not possible for MDA use, as in onchocerciasis–loiasis co- 
endemic areas, trials establishing moxidectin’s safety and effi-
cacy for treatment of individuals with loiasis microfilaremia 
have also been registered [118]. The analysis of the clinical 
trials that are planned can be assisted by mathematical mod-
eling [10,93] to ascertain more robustly the anti-filarial proper-
ties and any macrofilaricidal effect that moxidectin may exert. 
Economic considerations such as its manufacturing and 
distribution costs, as well as the feasibility of its (probably 
time-limited) donation (see 7. Expert opinion) will require 
further investigation [102]. Given moxidectin’s superior effi-
cacy compared to ivermectin, moxidectin clearly has the 
potential to revolutionize the treatment, control, and elimina-
tion of onchocerciasis due to O. volvulus.
7. Expert opinion
Phase II and III clinical trials have demonstrated the superiority 
of moxidectin compared to ivermectin, with stronger and 
longer microfilaridermia suppression, very little difference in 
side effects, smaller inter-individual variability in responses to 
treatment, and absence of suboptimal responders [16,17]. 
Table 3. Characteristics of ivermectin, moxidectin, and doxycycline.
Ivermectin Moxidectin Doxycycline
Drug description
Formula C48H74O14 C37H53NO8 C22H24N2O8
Molecular mass 875.10 g/mol 639.819 g/mol 444.43 g/mol
Drug family Avermectin macrocyclic lactone Milbemycin macrocyclic lactone Tetracycline antibiotic
Pharmacokinetics*
Dose 150–200 µg/kg (estimated 
by height)
8 mg 100–200 mg
Treatment 
course
Single dose Single dose Daily for 4–6 weeks
Route of 
administration
Oral Oral Oral
Half-life (t1/2) 18 hours 20–43 days 12–25 hours
Time to peak 
concentration  
(Tmax)
3–5 hours 3–4 hours 2.5 hours
Peak 
concentration  
(Cmax)
34–55 ng/mL 56.7 ng/mL 3.6 µg/mL
Volume of 
distribution  
(Vd)
3–3.5 L/kg 1.2 L/kg 0.7 L/kg
Protein binding 93% – >90%
Lipophilicity 
(LogP)
4.8 6 0.63
Metabolism Liver Liver (limited) Liver, gastro-intestinal tract
Excretion Feces, breast milk Feces, breast milk Feces, urine
Pharmacodynamics
Mechanism of 
anthelmintic 
action
Cell hyperpolarization and worm paralysis through 
opening of ligand-gated chloride channels. 
Potentially altered worm immunomodulatory 
protein production
Cell hyperpolarization and worm paralysis through 
opening of ligand-gated chloride channels. 
Potentially altered worm immunomodulatory 
protein production
Depletion of endosymbiotic 
Wolbachia pipientis bacteria in 
filarial nematodes [96]
Effect on 
Onchocerca 
volvulus
Microfilaricidal [9] Microfilaricidal [16,17,45] Non-directly microfilaricidal
Embryostatic [9]; permanent sterilizing effect 
(assumed to be cumulative in transmission 
models [82,83]); partially macrofilaricidal [10]
Assumed embryostatic effect in transmission 
models [45]
Macrofilaricidal [90–93]; assumed 
prophylactic in models [93]; 
retarding L3 development in 
vectors [94]
Drug distribution modalities in onchocerciasis-endemic areas
Distribution Community-directed treatment with ivermectin 
(CDTI); TNT if loiasis co-endemicity
Expected community-directed treatment with 
moxidectin (CDTM)
TTd
Approved for 
human use 
(group)
Yes (≥5 years old) Yes (≥12 years old) Yes (≥8 years old), but see [105]
Contraindications None None Hypersensitivity to tetracyclines
Risk in 
pregnancy
Class C (risk not ruled out); teratogenic in mice, rats, 
and rabbits at very high doses
Insufficient evidence Class D (positive evidence of risk); 
Discoloration of teeth during 
tooth development, but see 
[104,105]
Risk in loiasis co- 
endemicity
Risk of SAEs if ≥20,000 mf/mL of Loa loa [88] Risk of SAEs anticipated, but see [118] None [90–92,96,97]
*Pharmacokinetics references [23]: for ivermectin [19–22], for moxidectin, and [115] for doxycycline; mf: microfilariae; SAE: severe adverse event; TNT: test (for 
loiasis)-and-not-treat (with microfilaricides); TTd: test (for onchocerciasis)-and-treat with doxycycline (macrofilaricide). 
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Given that microfilariae are mostly responsible for onchocer-
ciasis-associated morbidity and possibly also excess mortality 
[1], moxidectin provides a better therapeutic option in clinical 
settings. From the epidemiological perspective of the treat-
ment of populations, a modeling study predicted that mox-
idectin (delivered as CDTM) has the potential to reduce 
substantially times to elimination (or specifically, to an opera-
tional microfilarial prevalence threshold taken as a proxy of 
elimination) across a range of endemicity settings [45]. 
Therefore, moxidectin represents an excellent ATS drug to fill 
some crucial unmet needs for the treatment, control, and 
elimination of onchocerciasis. In communities with very high 
transmission due to high vector biting rates and/or exposure 
to vector bites, moxidectin’s complete microfilarial suppres-
sion 6 months after treatment, and very low microfilarial loads 
even 12 months after treatment, has the prospect to reduce 
considerably the magnitude of inter-treatment transmission 
(from humans to vectors) compared to ivermectin, particularly 
if high levels of therapeutic coverage and adherence can be 
reached and sustained [45]. In settings with low–moderate 
coverage foci, it is anticipated that even individuals who are 
not treated at every round may harbor lower microfilarial 
loads for longer, hopefully reducing the impact of missed 
treatment rounds (although parasite population biology pro-
cesses enhancing transmission at low infection levels [1] will 
counteract this somewhat [45]). High levels of systematic non- 
adherence would still hamper moxidectin’s epidemiological 
impact, emphasizing the need to understand and minimize 
the factors leading to reduced adherence [78–83].
Regarding community treatment, it is envisaged that mox-
idectin will offer major advantages over other proposed ATS. 
Given that no data yet exist to evaluate the effect on 
O. volvulus transmission and incidence of repeated moxidectin 
treatment rounds, transmission dynamic modeling studies can 
be used to project infection trends in human and vector 
populations according to endemicity levels and programmatic 
factors such as treatment duration, frequency, coverage, and 
adherence, among others. The only study published to date 
used phase II clinical trial data to calibrate the (EPIONCHO) 
model, and suggested that aCDTM can be as effective as 
bCDTI in shortening times to reach given microfilarial preva-
lence thresholds [45]. Given that biannual ivermectin distribu-
tion incurs a greater (yet not simply double) cost than aCDTI 
[102], aCDTM may represent an economically superior choice 
compared to increasing ivermectin treatment frequency to 
bCDTI. This modeling study [45] assumed that CDTM could 
be deployed to the same age groups as CDTI, namely to those 
aged ≥5 years. Given that the current FDA approval is for 
those aged ≥12 years [15], the determination of an appropri-
ate dose for the treatment of children under 12 is a pressing 
need [117]. The health economic analysis presented in [45] 
assumed that moxidectin would be donated on the same 
terms as ivermectin (for as long as necessary wherever 
needed). Currently, it remains unclear whether moxidectin 
will be donated on these terms. However, given that [45] 
suggests that aCDTM could achieve substantial in-country 
cost savings (30–40% reductions in program costs when com-
pared to ivermectin), accelerate onchocerciasis elimination 
compared to aCDTI, and be less influenced by transmission 
and drug distribution seasonal patterns, some of the drug 
costs of moxidectin could be mitigated. Further work on 
economic evaluations of not only moxidectin, but all proposed 
ATS is an important area of research [102]. When comparing 
moxidectin to other (non-ivermectin-based) ATS [13], such as 
test-and-treat with doxycycline (TTd) and/or localized vector 
control [106], moxidectin would be able to capitalize upon the 
community-directed treatment framework already in place in 
endemic foci in Africa [2,11], particularly if it were donated as 
is ivermectin. Thus, in principle, CDTI could transition to CDTM 
across Africa without much anticipated disruption to existing 
drug distribution platforms. Some extra training of CDDs may 
be needed to ensure the delivery of the correct moxidectin 
dose, as there are some differences compared to the posology 
of ivermectin: 150 µg/kg of body weight to those aged 
≥5 years (which necessitates the use of dosing height poles 
and translates into a variable number of tablets) compared to 
four 2-mg tablets (regardless of weight and presently for those 
aged ≥12 years). However, as CDDs should be re-trained yearly 
or every 2 years, this should not incur a greatly increased cost.
In areas hypoendemic for onchocerciasis and co-endemic 
with loiasis at ≥20% prevalence, MDA is not advisable [13], but 
after establishing safe dosage and thresholds of L. loa micro-
filaremia levels [118], moxidectin could be used in TNT mod-
alities of delivery that may potentially be more effective than 
using ivermectin (due to the enhanced curtailing of transmis-
sion that would result from more prolonged suppression of 
microfilaridermia). Doxycycline (already available) and other 
anti-Wolbachia macrofilaricides (in pre-clinical and clinical 
development [110–114]) offer an exciting prospect, as TTd 
for the former, and ideally with much shorter treatment 
courses for the latter, albeit requiring high rates of 
O. volvulus screening, therapeutic coverage, and adherence 
[107]. Large-scale and long-term (at least 14 years) larviciding 
of vector breeding sites was effective for vector control in the 
OCP [1] but unlikely to be implemented elsewhere. Therefore, 
the feasibility, cost, environmental considerations, and optimal 
localization and duration of ground-based focal larviciding 
[106] or of non-insecticidal community-directed approaches 
[119] need to be further explored. The epidemiological impact 
of superior microfilaricidal (moxidectin) plus macrofilaricidal 
(anti-Wolbachia or direct-acting) combination therapies also 
warrants further investigation.
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